You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 22, 2024

qlosi Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Qlosi patents expire, and what generic alternatives are available?

Qlosi is a drug marketed by Orasis Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has twenty-four patent family members in fourteen countries.

The generic ingredient in QLOSI is pilocarpine hydrochloride. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the pilocarpine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Qlosi

A generic version of qlosi was approved as pilocarpine hydrochloride by PADAGIS US on November 16th, 2004.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for qlosi?
  • What are the global sales for qlosi?
  • What is Average Wholesale Price for qlosi?
Summary for qlosi
International Patents:24
US Patents:3
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
DailyMed Link:qlosi at DailyMed
Drug patent expirations by year for qlosi

US Patents and Regulatory Information for qlosi

qlosi is protected by three US patents and one FDA Regulatory Exclusivity.

Patents protecting qlosi

Ophthalmic pharmaceutical compositions and uses relating thereto
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PRESBYOPIA

Ophthalmic pharmaceutical compositions and uses relating thereto
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PRESBYOPIA

Ophthalmic pharmaceutical compositions and uses relating thereto
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PRESBYOPIA

FDA Regulatory Exclusivity protecting qlosi

NEW PRODUCT
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orasis Pharms QLOSI pilocarpine hydrochloride SOLUTION;OPHTHALMIC 217836-001 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Orasis Pharms QLOSI pilocarpine hydrochloride SOLUTION;OPHTHALMIC 217836-001 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Orasis Pharms QLOSI pilocarpine hydrochloride SOLUTION;OPHTHALMIC 217836-001 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Orasis Pharms QLOSI pilocarpine hydrochloride SOLUTION;OPHTHALMIC 217836-001 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for qlosi

See the table below for patents covering qlosi around the world.

Country Patent Number Title Estimated Expiration
Israel 264664 ⤷  Sign Up
Japan 7297308 ⤷  Sign Up
China 116726006 眼科药物组合物及其相关用途 (Ophthalmic pharmaceutical compositions and uses related thereto) ⤷  Sign Up
Canada 3031370 COMPOSITIONS PHARMACEUTIQUES OPHTALMIQUES ET UTILISATIONS ASSOCIEES (OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES RELATING THERETO) ⤷  Sign Up
South Korea 102588499 ⤷  Sign Up
Mexico 2023003124 COMPOSICIONES FARMACEUTICAS OFTALMICAS Y USOS QUE SE RELACIONAN A LAS MISMAS. (OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES RELATING THERETO.) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.